Trachelogenin

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Trachelogenin, an HCV entry inhibitor, has antiproliferative effects, and its mechanism is related to affecting the phosphorylation of key proteins in the β-Catenin signaling pathway, such as β-Catenin, c-Myc, and GSK3, in a concentration-dependent manner.

Trachelogenin, an HCV entry inhibitor, has antiproliferative effects, and its mechanism is related to affecting the phosphorylation of key proteins in the β-Catenin signaling pathway, such as β-Catenin, c-Myc, and GSK3, in a concentration-dependent manner.Trachelogenin exhibits antiviral, anti-inflammatory, and analgesic activities, with IC50 values of 0.325 and 0.259 μg/mL in HCVcc and HCVpp models, respectively. Trachelogenin has antiviral, anti-inflammatory and analgesic activities, with IC50s of 0.325 and 0.259 μg/mL in HCVcc and HCVpp models, respectively.Trachelogenin is a compound derived from Combretum fruticosum.

——

——

——

Others

Other Targets

——

——

——

34209-69-3

388.15

C21H24O7

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (257.46 mM)

——

——

(-20℃)

With Ice Pack

≥ 2 years